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The cause of sporadic amyotrophic lateral sclerosis (ALS) is largely unknown, but genetic factors are thought
to play a signiﬁcant role in determining susceptibility to motor neuron degeneration. To identify genetic var-
iants altering risk of ALS, we undertook a two-stage genome-wide association study (GWAS): we followed
our initial GWAS of 545 066 SNPs in 553 individuals with ALS and 2338 controls by testing the 7600 most
associated SNPs from the ﬁrst stage in three independent cohorts consisting of 2160 cases and 3008 con-
trols. None of the SNPs selected for replication exceeded the Bonferroni threshold for signiﬁcance. The
two most signiﬁcantly associated SNPs, rs2708909 and rs2708851 [odds ratio (OR) 5 1.17 and 1.18, and
P-values 5 6.98 3 10
27 and 1.16 3 10
26], were located on chromosome 7p13.3 within a 175 kb linkage dis-
equilibrium block containing the SUNC1, HUS1 and C7orf57 genes. These associations did not achieve
genome-wide signiﬁcance in the original cohort and failed to replicate in an additional independent cohort
of 989 US cases and 327 controls (OR 5 1.18 and 1.19, P-values 5 0.08 and 0.06, respectively). Thus, we
chose to cautiously interpret our data as hypothesis-generating requiring additional conﬁrmation, especially
as all previously reported loci for ALS have failed to replicate successfully. Indeed, the three loci (FGGY,
ITPR2 and DPP6) identiﬁed in previous GWAS of sporadic ALS were not signiﬁcantly associated with disease
in our study. Our ﬁndings suggest that ALS is more genetically and clinically heterogeneous than previously
recognized. Genotype data from our study have been made available online to facilitate such future endeavors.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a rare and devastating
neurodegenerative disease that predominantly affects motor
neurons leading to progressive paralysis, and ultimately death
from respiratory failure within 3–5 years of symptom onset.
Approximately 5% of ALS is familial in nature, whereas the
remaining 95% occurs sporadically throughout the community
(1). Although the genetic causes of many monogenic familial
forms of ALS have been described (2), the etiology of sporadic
ALS is largely unknown. Familial aggregation studies, twin
studies and epidemiological observations have suggested asub-
stantial genetic contribution to disease risk (3,4). Recently,
genome-wide association studies (GWAS) have putatively
identiﬁed variants with moderate effects on the risk of develop-
ing ALS in the 1p32.1 region (FGGY) (5), in the 12p11 region
(ITPR2) (6) and in the 7q36.2 region (DPP6) (7,8). However,
these loci require replication in independent cohorts to
conﬁrm disease association, and, at most, account for only a
fraction of the elevated risk of developing ALS, suggesting
that additional genetic factors exist.
We conducted a two-stage GWAS to search for common
variants with moderate risk (9,10). For the ﬁrst stage, we
used 555 352 SNPs that extract information on 91% of
common autosomal SNPs identiﬁed in the European popu-
lations based on the HapMap data [CEU, r
2 . 0.8, minor
allele frequency (MAF) . 5%] (10,11). These SNPs were gen-
otyped in two independent cohorts of European origin consist-
ing of 553 ALS cases and 2338 controls. For the second stage,
we analyzed the 7600 SNPs that were most associated with the
altered risk of disease in the initial genome-wide scan in an
additional 2160 cases and 3008 controls. The large number
of SNPs and samples genotyped in the second stage provided
sufﬁcient power to follow up on regions with moderate associ-
ation in the initial genome-wide scan (threshold P-value for
follow-up study ,0.005).
RESULTS
We conducted the initial genome-wide scan in a case-control
cohort of 553 ALS cases and 2338 neurologically normal
control of European ancestry. In the second stage, we geno-
typed 7600 of the most associated SNPs from the ﬁrst stage
in three additional replication cohorts totaling 2160 ALS
cases, and compared this with data for the same 7600 SNPs
in three control cohorts totaling 3008 samples. After quality























































































 control procedures, 6758 SNPs were available for analysis in a
ﬁnal combined stage 1 and stage 2 cohort of 2289 cases and
4532 controls. These SNPs covered 3152 distinct chromoso-
mal regions deﬁned by a maximal distance between two
SNPs of ,100 kb; 1745 regions contained only one SNP
and 40 regions contained 10 or more SNPs. Of these
regions, 94 had at least one SNP with an observed P-value
,10
23 (Fig. 1).
None of the SNPs tested in this study clearly achieved
genome-wide signiﬁcance after correction for multiple
testing (see Supplementary Material, Table S3 for association
results of all 6758 tested SNPs). The SNPs with the lowest
P-values identiﬁed by our two-stage GWAS were located on
chromosome 7p12.3 (Table 1), a region which has not been
previously linked to the pathogenesis of ALS. The SNPs
were located within a 175 kb linkage disequilibrium (LD)
block containing three genes, SUNC1, HUS1 and C7orf57.
The strongest signal was observed for rs2708909 located in
the third intron of the gene SUNC1 (P-value ¼ 6.98   10
27
in combined analysis, NM_152782.3), which encodes the
‘SAD1 and UNC84 domain containing 1’ protein. The
second SNP, rs2708851, was in complete LD with
rs2708909 (r
2 ¼ 0.97; Fig. 2), and was located 22 kb upstream
of SUNC1 within intron 4 of C7orf57 (NM_001100159.1).
These SNPs did not exceed the threshold for genome-wide sig-
niﬁcance in the overall cohort, were only marginally associ-
ated with ALS risk when analyzed in the individual North
American and Italian cohorts (P-values for rs2708909 ¼
5.40   10
25 and 0.0006, respectively), and were not associ-
ated in the German dataset (P-value for rs2708909 ¼ 0.503),
probably reﬂecting the smaller size of this cohort.
To further test the association with increased risk of disease,
we genotyped rs2708851 and rs2708909 in a dataset of 989
US cases with ALS or other motor neuron diseases (MNDs)
and 327 neurologically normal US controls, all of whom
were of non-Hispanic Caucasian ethnicity and had previously
served in the US military (12,13). This sample set represented
and independent sample, as none of these samples were
included in the initial genome-wide stage or in the replication
stage. Rs2708909 and rs2708851 failed to reach signiﬁcance
[P-value ¼ 0.08 for rs2708909 and 0.06 for rs2708851 based
on a logistic regression model correcting for age at onset
and gender, odds ratio (OR) ¼ 1.176 and 1.189, respectively],
though the sample size was underpowered to detect moderate
effect alleles (power to detect OR of 1.17 for a MAF of 0.45 ¼
41.1% at P-value of 0.05). The results are very similar when
only patients diagnosed with deﬁnite or probable ALS were
analyzed as cases (P-value for rs2708909 ¼ 0.09; P-value
for rs2708851 ¼ 0.06). Furthermore, no evidence for associ-
ation with the previously implicated SNPs in ITPR2 and
DPP6 was found in this dataset (rs109260404: P-value ¼
0.62; rs2306677: P-value ¼ 0.77) (14).
Rs2708909 and rs2708851 lie within a 175 kb region of LD
(multiallelic D0.0.8) on chromosome 7p12.3. Using our stage
1 datasets, we found that the HapMap CEU, the US and the
Italian populations share an almost identical haplotype struc-
ture across this region (Supplementary Material, Fig. S2),
and determined that seven SNPs (rs6955251, rs2686821,
rs2686831, rs2708909, rs2708851, rs2307252 and rs2708912)
account for 85% of the variation across the 175 kb region at
an r
2 . 0.5. The ﬁrst ﬁve of these markers had been geno-
typed as part of our stage 1 and stage 2 datasets. To investigate
whether other SNPs in the same region were more signiﬁ-
cantly associated with altered risk of developing ALS, we ana-
lyzed genotype data for the two additional SNPs rs2307252
and rs2708912 for all stage 1 cases and controls (based on pre-
vious whole genome data, n ¼ 2521), stage 2 controls (based
on previous whole genome data, n ¼ 2548) and 216 stage 2
Figure 1. Association analysis of combined joints analysis in two-stage GWAS of ALS (n ¼ 2289 ALS cases and 4532 controls) based on the logistic regression
model correcting for age, gender and population. SNPs listed in Table 1 are represented by red dots.























































































 US cases (based on additional sequencing data). Neither
rs2307252 nor rs2708912 achieved genome-wide signiﬁcance
(P-values ¼ 0.47 and 0.16) based on this cohort of 753 cases
and 4532 controls. Next, we applied imputation to our stage
1 data using MACH version 1.0, but none of the untyped
SNPs in the region of 7p12.3 provided stronger evidence of
association compared with rs2708909 and rs2708851 (Fig. 2).
Our two-stage GWAS identiﬁed several additional loci with
P-values less than 10
23 representing hypotheses that may
merit additional follow-up studies (Supplementary Material,
Table S4) (9,10). The three loci (FGGY, ITPR2 and DPP6)
identiﬁed in previous GWAS of sporadic ALS (5–8) did not
alter risk of developing disease in either the combined case-
control cohort or in the three individual populations examined
in our study (Table 2).
Raw sample-level genotype data from the initial GWAS
study (North American ALS cases, North American controls,
Italian ALS cases and Italian controls from the Piemonte/
Turin region) are available for download through the dbGAP
portal (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?study_id=phs000006.v1.p1). Individual genotype
data for the CGEMS dataset are available for registered users
through the CGEMS portal (http://cgems.cancer.gov/data.),
whereas individual genotype data for the KORA cohort may
be requested (http://epi.gsf.de/kora-gen/index_e.php).
DISCUSSION
Here we present the results of our two-stage GWAS involving
2713 cases and 5346 controls. This analysis was corrected
based on the 531 661 autosomal SNPs genotyped in the
initial whole genome scan, rather than the smaller number of
SNPs followed up in the replication stage, as we wanted to
be as conservative as possible. Our study represents the
largest GWAS published to date in ALS, and the ﬁrst to be
sufﬁciently powered to reliably detect moderately associated
SNPs in this relatively rare, fatal neurodegenerative disease.
Our study did not identify any SNPs that clearly exceeded
the standard threshold for genome-wide signiﬁcance (i.e.
,10
27), and there is little or no overlap with the results of pre-
viously published studies (5–8). This contrasts with GWAS in
other neurological diseases such as multiple sclerosis, where
the most associated SNP in the HLA-DRA locus had a
P-value , 10
280 (15). One possible explanation for this lack
of success may be that ALS is a more genetically and clini-
cally heterogeneous disease than previously appreciated,
which would signiﬁcantly limit the power of GWAS. The
identiﬁcation of multiple different familial ALS genes, each
involving disparate biological pathways, supports this notion
(16). Alternatively, causative genetic factors may increase
the risk of motor neuron degeneration by only a small
amount (i.e. OR , 1.2) meaning that even larger GWAS
involving 5000–10000 will be required to reliably identify
loci (17). Finally, we compensated for the relatively small
number of cases in the ﬁrst stage of our study by selecting
several thousand SNPs for detailed follow-up. Although this
approach is likely to be adequate for identifying alleles of
moderate effects (i.e. OR of . 1.4), mild effect alleles could
easily have failed to reach the threshold for inclusion in the
replication stage.
Our study also failed to replicate the three loci (FGGY,
ITPR2 and DPP6) that had been previously published as
been associated with increased risk of sporadic ALS (5–8).
This ﬁnding agrees with data from the National Registry of
Veterans with ALS, which also failed to replicate these loci
in a cohort of 989 cases and 327 controls (14). There are
several possible explanations for this ﬁnding. First, the lack
of replication of these loci in the current study may be
explained by the small number of SNPs selected from the
Table1. SNPswith a P-value ,10
26 based onthe logisticregressionmodelof
2289 ALS cases and 4532 controls
rs2708909 rs2708851
Chromosomal location 7p12.3 7p12.3
Position 48,018,204 48,052,327




Risk allele G C
Minor allele T T
Major allele G C
Minor allele frequency (cases) 0.449 0.451
Minor allele frequency (controls) 0.496 0.497
Allelic odds ratio (95% CI) 1.17 (1.11–1.23) 1.17 (1.11–1.23)
Population attributable risk (95%
CI)
0.08 (0.05–0.12) 0.08 (0.05–0.12)
All samples
P-value 6.98   10
27 1.16   10
26
Risk allele frequency (cases) 0.551 0.549




P-value 5.40   10
25 2.61   10
25
Risk allele frequency (cases) 0.54 0.54





Risk allele frequency (cases) 0.590 0.589





Risk allele frequency (cases) 0.505 0.50
Risk allele frequency (controls) 0.489 0.488
National Registry of Veterans with ALS
P-value 0.08 0.06
Risk allele frequency (cases) 0.499 0.499
Risk allele frequency (controls) 0.457 0.456
Inter-SNP LD (r
2) 0.961
Position was based on NCBI Build 36.3; allele frequencies, odds ratios
[with 95% conﬁdence intervals (CI)] and population attributable risk were
calculated using the combined stage 1 and stage 2 data; risk allele, the
allele with higher frequency in cases compared with controls; minor allele,
the allele with the higher frequency in controls; major allele, the allele
with higher frequency in controls; P-values for all samples were based on
the logistic regression model corrected for age, gender and population, and
were based on the logistic regression model corrected for age and gender
for the individual populations; all samples, 2289 ALS cases and 4532
controls included in the combined joint analysis; North American samples,
869 ALS cases and 2858 controls; Italian samples, 871 Italian ALS cases
and 1190 Italian controls; German samples consisted of 549 ALS cases
and 484 controls; National Registry of Veterans with ALS samples
consisted of 989 ALS cases and 327 controls; inter-SNP LD (r
2), linkage
disequilibrium between rs2708909 and rs2708851 measured as r
2
(Haploview 4.1) (36).























































































 initial genome-wide scans of the Dutch and TGEN studies for
follow-up to conﬁrm disease association. In the Dutch study of
461 cases and 450 controls, the 200 most associated SNPs
were brought forward to the replication stages (6), whereas
the TGEN study used a DNA pooling methodology involving
386 North American sporadic ALS cases and 542 controls to
select 192 SNPs for individual-level genotyping (5). The
several hundred thousand tests performed as part of any
GWAS make it more likely that the most associated SNPs in
the initial genome-wide scan represent false positive associ-
ations arising by chance (‘winner’s curse’). Indeed, previous
two-stage GWAS studies have repeatedly shown that truly
causative SNPs are often not ranked in the top 1000 SNPs
in the initial genome-wide scan (10), which led us to select
a large number of SNPs for replication in our stage 2 analysis.
Another possible explanation for the lack of replication of the
FGGY, ITPR2 and DPP6 is that the initial Dutch and TGEN
studies identiﬁed markers that are not in strong LD with the
causal variant, leading to a false refutation in our study that
was based on different populations (9).
The chromosome 7 risk variants putatively identiﬁed as
hypotheses by our study were not associated with disease
when analyzed in the individual German population included
in the study. Although population-to-population variation in
causative genes has been postulated for ALS (18,19), our ﬁnd-
ings are more likely to reﬂect the smaller number of the
samples from the individual populations included in the
study, and the consequent loss in power to detect moderate
effect loci: the smallest German cohort of 549 cases and 484
controls had only 16.4% power to detect the SUNC1 locus
Figure 2. Location of the association signal and pairwise linkage disequilibrium (LD) surrounding the most associated SNPs on chromosome 7p12.3. LD pattern
is depicted using stage 1 US data. Association signals are shown for all SNPs genotyped in (A) stage 1 US samples (blue squares, n ¼ 1065); (B) stage 1 Italian
samples (green triangles, n ¼ 1456); (C) stage 2 all populations (orange circles, n ¼ 4300), and the combined dataset (red diamonds, n ¼ 6821). The most associ-
ated SNPs, rs2708909 and rs2708851, lie in or near gene SUNC1, and are in almost complete LD (D0 ¼ 0.981, r
2 ¼ 0.959 based on stage 1 US data). Plots were
produced using the snp.plotter package within R version 2.6.1.























































































 (assuming an OR of 1.18 and a MAF of 0.45), whereas the
larger North American dataset of 3727 samples had 55.1%
power under the same parameters. Indeed, the putative associ-
ation of rs2708909 and rs2708851 with ALS is only apparent
in the combined analysis of 2289 cases and 4532 controls
(power to detect SUNC1 locus ¼ 94.8%), emphasizing the
necessity of using several thousand samples to detect variants
that only moderately increase risk of developing sporadic
ALS (20).
Even if we assume that the chromosome 7 variants are truly
associated with ALS, we are left with the problem of deter-
mining which gene within this LD block is responsible for
increased risk of disease. The location of the variant with
the most signiﬁcant P-value within the intron of SUNC1
would suggest that this gene is the most likely candidate.
Indeed, SUNC1 encodes a 40.5 kDa nuclear envelope protein
‘Sad1 and UNC84 domain containing 1’ (21), and mutations
in nuclear envelope proteins underlie a variety of neuromuscu-
lar diseases including Charcot-Marie-Tooth disease, type 2B1
(22) and spastin-associated hereditary spastic paraplegia (23).
However, these biological hypotheses should be interpreted
cautiously: although the gene lying closest to an associated
SNP is generally considered to be the prime suspect in
disease pathogenesis, a number of alternative pathogenic
mechanisms must be considered: our own studies have
shown that the associated SNP may ‘tag’ the true causative
variant residing many kilobases distant in another gene; the
associated SNP could affect expression of cis genes up to
100 Kb distant, or could act in trans to alter gene expression
on other chromosomes (24); alternatively, the SNP could
alter the function or tissue-speciﬁc expression of a previously
unidentiﬁed microRNA or genetic element. Furthermore,
despite the large number of samples analyzed in our study,
replication of the locus in independent cohorts remains a
necessity (9). The two SNPs reported in the current study
did not achieve signiﬁcant association with disease in a separ-
ate cohort of 221 Irish ALS cases and 211 neurologically
normal controls, though the small size of this cohort precludes
ﬁrm conclusions being drawn from this data (Irish data was
not included in the current study as necessary covariates
were not available from the investigators associated with the
study) (7). Public release of raw genotype data is helpful in
this regard, as it reduces the expense of future whole
genome association studies and allows researchers to have
greater conﬁdence in the results of their association studies
by increasing sample size and power to accurately detect cau-
sative loci (25). Our initial public release of data established a
powerful, unique resource for the ALS research community
(25), and this data has been incorporated into all other ALS
GWAS published to date (5–8). Coincident with publication,
we have augmented this initiative with data from all 2713 ALS
cases genotyped in the current study.
In summary, we present the results of our two-stage
genome-wide association in a large cohort of sporadic
ALS patients. None of the studied loci clearly achieved
genome-wide level of signiﬁcance, and none of the previously
published loci were signiﬁcantly associated with disease in our
study. Though the data supporting an association of the
chromosome 7p12.3 variants are suggestive, we chose to inter-
pret these results cautiously as loci previously reported to be
associated with increased risk of developing ALS have uni-
formly failed to replicate (26). Thus, these variants should
be considered as hypothesis-generating that require additional
replication to conﬁrm or refute their veracity. The current lack
of success of GWAS in sporadic ALS may indicate that the
disease is more heterogeneous than previously recognized,
and highlights the fact that even larger sample numbers will
be required to deﬁnitively dissect the genetics underlying
this fatal neurodegenerative disease.
MATERIALS AND METHODS
Initial genome-wide scans
We used HumanHap550 version one BeadChips (Illumina
Inc., San Diego, CA, USA) to genotype 555 352 SNPs in (i)
276 North American ALS cases and 828 North American neu-
rologically normal control samples obtained from the NINDS
Neurogenetics repository at the Coriell Institute for Medical
Research (NJ, USA). The initial part of this scan has been pre-
viously published, and the raw genotype data made publicly
available (25); and (ii) 277 Italian ALS cases and 263
Italian control samples collected within the Turin/Piemonte
area of Northern Italy. We also genotyped 561 466 SNPs in
an additional cohort of 1247 control samples obtained from
the InChianti study, a representative population-based cohort
of older persons living in the Chianti geographic area
(Tuscany, Central Italy) (27), using the HumanHap550
version three BeadChip (28). Analysis was conﬁned to the
545 066 SNPs that are common to versions one and three
Table 2. P-values from the two-stage GWAS for SNPs that have been previously associated with increased risk of developing ALS (5–7)
SNP Chr Gene Risk allele (frequency affected) P-value
All samples US samples Italian samples German samples
rs6700125 1 FGGY T (0.36) 0.08 0.23 0.55 0.35
rs2306677 12 ITPR2 T (0.11) 0.74 0.30 0.27 0.97
rs10260404 7 DPP6 C (0.39) 0.40 0.36 0.96 0.28
Chr,chromosome; risk allele, the allele with higher frequency in cases compared with controls (5–7); frequency affected, frequency of risk allele in2289
ALS cases included in the current study; P-values for all samples were based on the logistic regression model corrected for age, gender and population,
and were based on the logistic regression model corrected for age and gender for the individual populations; all samples, 2289 ALS cases and 4532
controls included in the combined joint analysis; North American samples, 869 ALS cases and 2858 controls; Italian samples, 871 Italian ALS cases and
1190 Italian controls; German samples consisted of 549 ALS cases and 484 controls.























































































 HumanHap550 BeadChips. Demographics and clinical fea-
tures of the case and control cohorts are shown in Supplemen-
tary Material, Table S1. All patients included in the initial and
follow-up stages of the study had been diagnosed with prob-
able, clinically probable, laboratory supported or deﬁnite
sporadic ALS accorded to the El Escorial criteria (29). Only
unrelated, non-Hispanic, white Caucasian individuals of
European descent were included in the study.
Standard quality control procedures (e.g. exclusion of
samples with low call rates, mismatch between gender
according to phenotype data and gender deﬁned by genotype,
non-European ancestry, cryptic relatedness and incomplete
phenotype data; and exclusion of SNPs with low call
rates, Hardy-Weinberg equilibrium P-value , 0.001 and
non-random missingness) were applied to the data (Sup-
plementary Material, Fig. S1). After applying these ﬁlters,
the cohorts included in the initial genome-wide scans con-
sisted of (i) 271 North American sporadic ALS cases and
794 North American control individuals and (ii) 266 Italian
sporadic ALS cases and 1190 Italian control samples. A
total of 474,554 SNPs were available for association testing
in the North American cohort, and 466 131 SNPs in the
Italian cohort. Q-Q plots were prepared using R version
2.6.1 (2007, The R Foundation for Statistical Computing)
based on genomically controlled association data (Fig. 3).
Genomic inﬂation factor l for the US cohort was 1.002 and
for the Italian cohort was 1.147. The most signiﬁcantly associ-
ated SNPs identiﬁed in the genome-wide scans of the North
American and Italian cohorts are listed in Supplementary
Material, Table S2.
Replication stage
A total of 7600 SNPs were selected on the basis of single-SNP
association tests in the initial genome-wide scans. Of these,
2533 were selected as they were the most signiﬁcantly associ-
ated SNPs in the North American cohort based on the
Cochran-Armitage test; 2533 were the most signiﬁcant SNPs
in the Italian cohort and 2534 SNPs were chosen based on
their disease association in the combined Italian and North
American GWAS cohorts. These SNPs were genotyped
using a custom-designed iSelect Inﬁnium assay (Illumina) in
three cohorts of sporadic ALS patients of European back-
ground totaling 2160 cases. The case dataset was compared
with data for the same SNPs obtained from 3008 neurologi-
cally normal control individuals. The cases consisted of 963
North American sporadic ALS patients, 631 Italian sporadic
ALS patients and 566 German individuals diagnosed with
sporadic ALS. Population control data was obtained from:
the Cancer Genetic Markers of Susceptibility study
(CGEMS; n ¼ 2243 North American control samples) (30);
European Network for Genetic-Epidemiological Studies
(HYPERGENES, n ¼ 275 Italian control samples) and the
Cooperative Health Research in the Region of Augsburg
study (KORA; n ¼ 490 German control samples) (31).
These studies were approved by the appropriate institutional
review boards.
After applying quality control ﬁlters to the replication data,
6758 SNPs were suitable for analysis in the replication cohort
consisting of 1752 cases and 2548 controls (Supplementary
Material, Fig. S1). Association analysis was carried out in
two ways: for each population separately, and for the stage
1 and stage 2 replication data combined (32). The combined
stage 1 and stage 2 samples consisted of 2289 ALS cases
and 4532 controls, which yielded 94.8% power to detect loci
with an OR of 1.17 and a MAF of 0.45 under the log-additive
model assuming a two-sided a of 0.005 (threshold P-value for
selection of SNPs for follow-up). The PLINK toolset (33) was
used to test for association using logistic regression, adjusted
for age, gender and population. This approach retains power
to detect recessive or overdominant alleles at the cost of a
small decrease in power relative to the Cochrane-Armitage
trend test (34) for the detection of alleles with multiplicative
effect (10). Bonferroni correction for multiple testing yielded
a threshold P-value of 10
27 (a ¼ 0.05/531 661 autosomal
SNPs genotyped in stage 1) (35).
Detailed descriptions of sample collection methodology and
the quality control ﬁlters used in this study are available in
Supplementary Material, Methods.
Additional replication dataset
Rs2708851 and rs2708909 were genotyped by TaqMan assays
(ABI) in an additional dataset of 989 non-Hispanic Caucasian
individuals diagnosed with ALS or other MNDs and 327 neu-
rologically normal control samples. The case samples have
been collected by the National Registry of Veterans with
ALS (12), and the control samples by the GENEVA study
(13). Of these 989 patients, 663 (67%) were diagnosed with
deﬁnite or probable ALS by El Escorial criteria, 79 (8%)
had possible ALS, 158 (16%) had progressive muscular
Figure 3. Q-Q plot based on (A) genomic-controlled Cochran-Armitage Trend
test P-values for 474554 SNPs analyzed in the stage 1 271 North American
ALS cases and 794 North American controls (genomic inﬂation factor l ¼
1.002); (B) genomic-controlled Cochran-Armitage Trend test P-values for
466131 SNPs analyzed in the stage 1 266 Italian ALS cases and 1190
Italian controls (genomic inﬂation factor l ¼ 1.147) and (C) logistic
regression P-values for 6758 SNPs analyzed in the stage 2 1752 ALS cases
and 2548 controls.























































































 atrophy and the remaining 89 (9%) had primary lateral
sclerosis or progressive bulbar palsy. These samples had not
been genotyped in either the initial genome-wide stage or in
the replication stage.
Haplotype block determination and imputation
Haploview v4.1 was used for assessment of LD (36). Haplo-
type blocks were deﬁned using the Haploview v4.1 solid
spine of LD method (D0 . 0.8). SNPs selected to ﬁne-map
the haplotype block on chromosome 7p12.3 were genotyped
by sequence analysis. PCRs were ampliﬁed using primers
designed using Primer3-web v0.3.0 (http://frodo.wi.mit.edu)
and FastStart PCR MasterMix polymerase (Roche Diagnostics
Corp., IN, USA) were sequenced using BigDye terminator
v3.1 sequencing chemistry, and run on an ABI3730xl
(Applied Biosystems, CA, USA) genetic analyzer as per man-
ufacturer’s instructions. The sequences were analyzed with
Sequencher software, version 4.2 (Genecodes, VA, USA).
MACH version 1.0 software (http://www.sph.umich.edu/csg/
abecasis/MACH/download/) (37) was used to estimate haplo-
types, and map crossover and error rates using 100 iterations
of the Markov chain Monte Carlo algorithm in subsets of
250 random samples from the stage 1 US and Italian
cohorts. These estimates were combined with haplotypes
from the HapMap CEU samples to infer genotypes in the
region of interest for both cohorts using maximum likelihood
estimates of genotypes present in HapMap samples (www.
hapmap.org, release 21), but not in the Illumina data. After
genotype imputation, the maximum likelihood genotypes for
the stage 1 US and Italian cohorts were merged. Analyses
were rerun, excluding imputed SNPs with r
2 values ,0.30
between imputed and known genotypes, and posterior prob-
ability averages ,0.80 for the most likely genotype imputed.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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